Synchron, Inc. news
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. This procedure represents a significant technological milestone for scalable BCI devices and is the first to occur in
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy.
The partnership will enable Synchron to collaborate with Team Gleason’s expert committees and an international network of innovators and influencers. Through their community
- Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S.
- Paralysis is a devastating condition for more than 5 million patients in the United States
- Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks
- No Serious Adverse Events Reported after 12 Months
Synchron, a brain computer interface (BCI) company, today announced the expansion of its advisory board comprised of industry pioneers, to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth.
The members of the advisory board are visionaries across the technology
Synchron, a brain computer interface company, today announced a Twitter takeover by Philip O’Keefe, one of the patients implanted with the Stentrode brain computer interface. Mr. O’Keefe is the first person to successfully message the world on social media directly through thought using an implantable brain computer interface.
Mr. O’Keefe, a 62-year-old man with amyotrophic lateral sclerosis (ALS), successfully turned his direct thought to text via Twitter when he me
Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the Stentrode™ motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety and efficacy in patients with severe paralysis. Outcomes will include the use of the brain data to c